The estimated Net Worth of Mary B Esq Templeton is at least 455 千$ dollars as of 22 May 2020. Ms. Templeton owns over 1,103 units of Windtree Therapeutics stock worth over 3,459$ and over the last 6 years she sold WINT stock worth over 0$. In addition, she makes 451,907$ as Senior Vice President、 General Counsel and Corporate Secretary at Windtree Therapeutics.
Sign up
Ms. Templeton WINT stock SEC Form 4 insiders trading
Mary has made over 1 trades of the Windtree Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently she bought 1,103 units of WINT stock worth 7,997$ on 22 May 2020.
The largest trade she's ever made was buying 1,103 units of Windtree Therapeutics stock on 22 May 2020 worth over 7,997$. On average, Mary trades about 552 units every 0 days since 2019. As of 22 May 2020 she still owns at least 1,134 units of Windtree Therapeutics stock.
You can see the complete history of Ms. Templeton stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mary Templeton biography
Mary B. Templeton Esq. serves as Senior Vice President, General Counsel and Corporate Secretary of the Company. Ms. Templeton brings to us 40 years of legal and executive experience. Ms. Templeton previously held senior executive positions in the financial services industry, including as Senior Vice President and General Counsel of The Charles Schwab Corporation and as Senior Vice President and General Counsel of The Sequor Group Inc. (owned by Security Pacific Corporation) and in private practice in Philadelphia and New York. Prior to that, at Charles Schwab & Co., Ms. Templeton led development of the first broker-operated mutual fund marketplace, and, at Bradford Trust Company (New York), the first for-profit clearing corporation registered with the SEC. Ms. Templeton received a B.A. degree from Chatham University, where she is a member of the Board of Trustees, where she served as Editor-in-Chief of the Law Journal. She is a member of the Bar Associations of Pennsylvania and New York.
What is the salary of Mary Templeton?
As the Senior Vice President、 General Counsel and Corporate Secretary of Windtree Therapeutics, the total compensation of Mary Templeton at Windtree Therapeutics is 451,907$. There are 5 executives at Windtree Therapeutics getting paid more, with Craig Fraser having the highest compensation of 1,063,640$.
How old is Mary Templeton?
Mary Templeton is 73, she's been the Senior Vice President、 General Counsel and Corporate Secretary of Windtree Therapeutics since 2011. There are no older and 16 younger executives at Windtree Therapeutics.
What's Mary Templeton's mailing address?
Mary's mailing address filed with the SEC is 2600 KELLY ROAD, SUITE 100, WARRINGTON, PA, 18976.
Insiders trading at Windtree Therapeutics
Over the last 6 years, insiders at Windtree Therapeutics have traded over 1,982,541$ worth of Windtree Therapeutics stock and bought 6,849,036 units worth 20,224,921$ . The most active insiders traders include James Huang、Pharmaceutical Holdings Ltd...、Ii Investments Ltd Lph. On average, Windtree Therapeutics executives and independent directors trade stock every 24 days with the average trade being worth of 425,323$. The most recent stock trade was executed by Craig Fraser on 27 September 2023, trading 2,500 units of WINT stock currently worth 2,550$.
What does Windtree Therapeutics do?
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.
What does Windtree Therapeutics's logo look like?
Complete history of Ms. Templeton stock trades at Windtree Therapeutics
Windtree Therapeutics executives and stock owners
Windtree Therapeutics executives and other stock owners filed with the SEC include:
-
Craig Fraser,
President, Chief Executive Officer, Director -
Craig E. Fraser,
Pres, CEO & Director -
Steven Simonson,
Senior Vice President and Chief Medical Officer -
Eric L. Curtis M.B.A.,
Sr. VP & COO -
John P. Hamill,
Sr. VP, CFO & Corp. Sec. -
Mary Templeton,
Senior Vice President, General Counsel and Corporate Secretary -
James Huang,
Independent Chairman of the Board -
Brian Schreiber,
Independent Director -
Bruce Peacock,
Independent Director -
Joseph Mahady,
Independent Director -
John Leone,
Independent Director -
Daniel Geffken,
Independent Director -
Pratap Paruchuru,
Executive Director of Clinical Development -
Eric Curtis,
Chief Operating Officer, Senior Vice President -
John Hamill,
Chief Financial Officer, Senior Vice President -
Dr. Steven G. Simonson,
Sr. VP & Chief Medical Officer -
Diane Carman Esq.,
Sr. VP & Gen. Counsel -
Dr. Ronald L. Dundore,
Exec. Director of Regulatory Affairs & Quality -
Tracy Rarick,
Head of Operations & Program Management -
George Cox,
VP of Technical Operations -
Diane Carman,
SVP & General Counsel -
Leslie J. Williams,
Director -
Evan Loh,
Director -
Ii Investments Ltd Lph,
10% owner -
Pharmaceutical Holdings Ltd...,
10% owner -
John A Tattory,
SVP & CFO -
Mark Strobeck,
Director -
Capital Inc. Bioengine,
10% owner -
Laboratories, Inc. Center,
10% owner -
Robert A Scott,
Director